KEAP1 and type 2 diabetes mellitus: Our study revealed a significant relative increase in liver GSK‐3β (Figure 4a, p < .0001), Fyn (Figure 4b, p < .01), and Keap‐1 (Figure 4d, p < .0001) levels by 53%, 53%, and 38%, respectively, in response to the induction of type 2 diabetes compared to the levels observed in healthy control rats.